A Randomized, Double-blind, Parallel-group Study to Compare Efficacy, Safety, and Immunogenicity of GME751 (Proposed Pembrolizumab Biosimilar) and EU-authorized Keytruda® in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Metastatic NSCLC
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
AISHAH BINTI IBRAHIM
CONTACT
SC: Syafiqah Hanani Mohd Shahidin
CRC: 09-5572923 Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations
Non-Small Cell Lung Cancer (NSCLC)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WONG YOKE FUI, Florence
CONTACT
SC: Siti Amirah binti Ishak
General line : 03 – 8892 5555
CRC: 03 – 8892 5555
Ext 5418 (Tel)
03- 8892 5622 (Fax)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Anna Ting Huong Juan
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
AZZA BINTI OMAR
CONTACT
SC: Nora Diana binti Kamaruzaman
A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Nonsquamous Non-small Cell Lung Cancer.
Metastatic Nonsquamous Non- small Cell Lung Cancer
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Nurul Afifah Rozkhaidi
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
FONG CHIN HENG
CONTACT
SC: Farah Amalina bt Mohamed Affandi
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
AZZA BINTI OMAR
CONTACT
SC: Maisarah Noor
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
CHEN MAY FENG
CONTACT
SC: Ezzah Aisyah Najwa Dzulkafli
General line: 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my (Email)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
HOW SOON HIN
CONTACT
SC: Adibah Hamiza binti Ahmad Suhaimey
CRC: 09-5572923
Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects with Stage IV or Advanced Stage IIIB/C Nonsquamous Non- Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreak202)
Non-Small Cell Lung Cancer (NSCLC)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
HOW SOON HIN
CONTACT
SC: Suriani Yaacob
CRC: 09-5572923
Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Phase III, Open Label, Sponsor-Blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-Based Doublet Chemotherapy for Patients with EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TRIPION LUNG 15)
Locally advanced or metastatic NSCLC
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
+603 – 7786 0846
drazura@beaconhospital.com.my
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)
Phase Ib, Line of therapy: 1st line, Non-squamous with HER2 overexpression
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WONG YOKE FUI, Florence
CONTACT
SC: Siti Amirah
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
DR SOO HOO HWOEI FEN
hwoeifen@yahoo.com
CONTACT
SC: Farah Amalina bt Mohamed Affandi, Nur Adilah Abdul Aziz
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
SC: Tan Boon Sin
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2)
Phase II, Line of therapy: 1st Line & 2nd line, EGFR mutation
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
03-77872830
tholm@beaconhospital.com.my
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
SC: Erfan Salbi
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
PROF DR HOW SOON HIN
how_sh@yahoo.com
CONTACT
SC: Suriani Yaacob
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-17)
Phase II, Line of therapy: 1st Line, squamous or nonsquamous, KRAS G12C mutation and PD-L1 TPS ≥ 1%
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR SUHANA BINTI YUSAK
suhanayusak@gmail.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)
Phase III, Line of therapy: 1st line, Squamous & Nonsquamous
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
DR AISHAH BINTI IBRAHIM
aishibr@gmail.com
CONTACT
CRC: 09-5572923 Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR AIDEN HENG FOOK YEW
hengfy.onco@gmail.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR WONG YOKE FUI
florencefui@yahoo.com
+603 8892 5555 ext 4281
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum – pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st / 2nd generation EGFR‑TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E)
Phase III, Line of Therapy: 2nd line, EGFR mutation, Prgreesed afrer one line of TKI Inhibitor (1st or @nd generation)
Sunway Medical Centre
PRINCIPAL INVESTIGATOR
Dr. Jennifer Leong
CONTACT
CRC: 03-8601 1079 (Tel)
03-8601 1069 (Fax)
sunmed-crc@sunway.cm.my
edwinbt@sunway.com.my (email)
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)
Phase III, Line of therapy: 2nd & 3rd line, Progreesion after osimenitib at most recent therapy.
Mount Miriam Cancer Hospital Penang
PRINCIPAL INVESTIGATOR
Dr Ang Tick Suan
angts@mountmiriam.com
04-8923907
CONTACT
General line: 04 – 892 3999
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Tan Jiunn Liang
CONTACT
General line: 03-7841 4000
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dato’ Dr Mohamed Ibrahim A Wahid
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
Subang Jaya Medical Centre
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
PROF DR HOW SOON HIN
how_sh@yahoo.com
CONTACT
CRC: 09-5572923 Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)
Phase III, Lin eo ftherpy: 3rd line, Has received one line of platinum-based cchemothherapy and one line of immune checkpoint habitor, KRAS G12C (Central confirmation)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Administered Via Manual Injection Compared With Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy (PALOMA-3)
Phase III, Line of Therapy : 3rd line, Progressed after osimernitib and platinum based chemotherapy
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR JOHN LOW SENG HOOI
john.low@pantaidr.my
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Tan Jiunn Liang
CONTACT
General line: 03-7841 4000
Prince Court Medical Centre (PCMC)
PRINCIPAL INVESTIGATOR
Dr Muhammad Azrif Ahmad Annuar
CONTACT
General line : 03 – 2160 0000
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
Sunway Medical Centre
PRINCIPAL INVESTIGATOR
Dr Kow Ken Siong
CONTACT
edwinbt@sunway.com.my (Email)
+603 – 74919191/ 603-8601 1081
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Phase 1/2 Study of Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab combination therapy in metastatic non smal cell lung cancer. (POLYDAMAS)
Phase 1/2 study
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Tan Jiunn Liang
CONTACT
SC Mira (chest Team)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study) (ATORG001)
Molecular Profiling Study
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Ho Gwo Fuang
CONTACT
CIC (Research Room) : 03-79492120 (Tel)
SC: Chye Wei Ying
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
03-77860845
drazura@beaconhospital.com.my
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer (ATORG004)
Molecular Profiling Study
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Ho Gwo Fuang
CONTACT
CIC (Research Room) : 03-79492120 (Tel)
SC: Toh Yok Yong
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
03-77860845
drazura@beaconhospital.com.my
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Stage IV NSCLC, PDL-1 ≥50%
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Junie Khoo Yu-Yen
CONTACT
03-7787 2830
jkyy1081@gmail.com
SA Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
How Soon Hin
CONTACT
Suriani
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Tan Ai Lian
ailian.tan@gmail.com
CONTACT
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Muthukkumaran A/L Thiagarajan
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Faizah
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Lim Chun Sen
CONTACT
Sri Ratha
A phase II, open-label, single-arm, multi-centre study to evaluate the safety and efficacy of osimertinib with amivantamab as first-line treatment in participants with epidermal growth factor receptor mutation-positive, locally advanced or metastatic non-small cell lung cancer (OSTARA)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Audi Adawiah Bt Sulaiman Shah
CONTACT
SC: Puteri Nur Najwa Nor Azman
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Zubaidah
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
LEE CHEEN LENG
CONTACT
Ahmad Syarif Bin Ibrahim
CRC: 042225767 / 762
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
Azza Binti Omar
CONTACT
Nora Diana binti Kamaruzaman
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Voon Pei Jye
CONTACT
SC: Nur Izzah Binti Mohammed
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Zubaidah
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
How Soon Hin
CONTACT
Adibah Hamiza binti Ahmad Suhaimey
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
MASTURA BINTI MD YUSOF
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 1320/1321/1322
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Muthukkumaran A/L Thiagarajan
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Alia Nabilla
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Suhana Binti Yusak
CONTACT
Erda Syerena
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
Azza Binti Omar
CONTACT
Nora Diana
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Voon Pei Jye
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Zubaidah
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Kumutha A/P Chalaya
CONTACT
Khairulazmir
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
How Soon Hin
CONTACT
Adibah Hamiza
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
Azza Binti Omar
CONTACT
Maisarah Noor
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
Fong Chin Heng
CONTACT
Nurul Ainaa Jasmin
Clinical validation on the diagnostic efficiency of exosome blood-based panel that predict patient risk for non-small cell lung cancer (NSCLC)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Heng Fook Yew
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Locally advanced or metastatic, first line treatment, EGFR Exon 20 Insertion
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
MUTHUKKUMARAN A/L THIAGARAJAN
CONTACT
SC: Amirah
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
SC :Ahmad Syarif
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
AZZA BINTI OMAR
CONTACT
SC: Maisarah Noor
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
SC: Ngu Lin Hui
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First-Line Chemotherapy (DeLLphi-304)
Small Cell Lung Cancer (SCLC)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
AISHAH BINTI IBRAHIM
CONTACT
Nor Naimah Saidah
CRC: 09-5572923 Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Study of Non-Small Cell Lung Cancer Genomic Screening to Encourage Precision Medicine in Asia Pacific (LC-SCRUM-AP)
Non-Small Cell Lung Cancer
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
MUTHUKKUMARAN A/L THIAGARAJAN
CONTACT
Sharifah Alia , Puteri Nur Aliah
KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression = 1% and an STK11 co-mutation
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11 Co-mutation
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
FONG CHIN HENG
CONTACT
SC: Nurul Bisyarah Husna
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Angelyna Michelle
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Sultanah Bahiyah Hospital, Alor Setar
PRINCIPAL INVESTIGATOR
ARVINDRAN A/L ALAGA
CONTACT
SC: Nor Aishah Binti Mohd Ismail
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Antibody in Participants With Advanced or Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Non-Small-Cell Lung Carcinoma
Hospital Wanita dan Kanak-kanak Sabah
PRINCIPAL INVESTIGATOR
Dr Nahjatul Kursyiah Abd. Ghafar
CONTACT
SC: Roslin Guadih (016-8151234)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
TAN AI LIAN
CONTACT
SC: Nurul Bisyarah Husna
CRC: 042225767 / 762
Raja Perempuan Zainab II Hospital, Kota Bharu
PRINCIPAL INVESTIGATOR
AZZA BINTI OMAR
CONTACT
Maisarah Noor
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
IRFHAN ALI B HYDER ALI
CONTACT
SC: Siti Norazah
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Nur Haziqah
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
KUMUTHA A/P CHALAYA
CONTACT
SC: Narmatha Gurumoorthy
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50%
Advanced Non-Small Cell Lung Cancer
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
EZNAL IZWADI BIN MOHD MAHIDIN
CONTACT
SC: Nur Alia Nabilla, Nurul Aiman Farhana
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Yong Xian Lerk
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
HOW SOON HIN
CONTACT
SC: Syafiqah Hanani Mohd Shahidin
CRC: 09-5572923
Ext: 2922/2928 (Tel)
09-5139378 (Fax)
crchtaa@gmail.com (Email)
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Carcinoma, Non-Small-Cell Lung
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Preston Anak Stanley, Nur Syaza Mirza
CRC: 082-276820
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
SC: Farah Amalina Mohamed, Nur Rasyidah
CRC: 042225767 / 762
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
HOW SOON HIN
CONTACT
SC: Noor Sami’ah Mukhtar
CRC: 09-5572923 Ext: 2922/2928